Revelation Biosciences disclosed in news release today that Petra Acquisition shareholders last week approved merging with the drug development company.
The announcement was dropped in the second paragraph of a news release about Revelation’s most recent clinical study results on antiviral medications.
Revelation said the SPAC shareholder vote on Jan. 6 was unanimously in favor of the business combination, valued at $128 million.
Revelation’s stock and warrants are expected to begin trading today under “REVB” and “REVBW” on the Nasdaq.
As of this afternoon, Petra Acquisition has revealed no details about the shareholder vote. The SPAC’s last SEC filing was an 8-K in December. Read more.
